It has been nearly 3 years since the first ranibizumab biosimilar was approved for use in the U.S.
Byooviz (ranibizumab-nuna, Samsung Bioepis, Biogen) was approved in 2021 followed by Cimerli (ranibizumab-eqrn, Sandoz) in 2022. Since then, aflibercept biosimilars have been approved but have not been commercialized. In general, biosimilars remain a hot topic in ophthalmology, as well as across medicine.
“There are many hundreds of thousands, maybe millions, of patients on biologic drugs like aflibercept or systemic ones like Humira,” David A. Eichenbaum, MD, said. “Theoretically,